RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
International Stem Cell Stock

International Stem Cell ROE 2024

International Stem Cell ROE

-1.16

Ticker

ISCO

ISIN

US4603782016

In 2024, International Stem Cell's return on equity (ROE) was -1.16, a -177.05% increase from the 1.5 ROE in the previous year.

International Stem Cell Aktienanalyse

What does International Stem Cell do?

International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding International Stem Cell's Return on Equity (ROE)

International Stem Cell's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing International Stem Cell's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

International Stem Cell's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in International Stem Cell’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about International Stem Cell stock

What is the ROE (Return on Equity) of International Stem Cell this year?

The ROE of International Stem Cell this year is -1.16 undefined.

How has the Return on Equity (ROE) of International Stem Cell developed compared to the previous year?

The ROE of International Stem Cell has increased by -177.05% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of International Stem Cell?

A high ROE indicates that International Stem Cell generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of International Stem Cell?

A low ROE can indicate that International Stem Cell is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of International Stem Cell affect the company?

A change in ROE (Return on Equity) of International Stem Cell can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of International Stem Cell?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of International Stem Cell?

Some factors that can influence International Stem Cell's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does International Stem Cell pay?

Over the past 12 months, International Stem Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, International Stem Cell is expected to pay a dividend of 0 USD.

What is the dividend yield of International Stem Cell?

The current dividend yield of International Stem Cell is .

When does International Stem Cell pay dividends?

International Stem Cell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of International Stem Cell?

International Stem Cell paid dividends every year for the past 0 years.

What is the dividend of International Stem Cell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is International Stem Cell located?

International Stem Cell is assigned to the 'Health' sector.

Wann musste ich die Aktien von International Stem Cell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of International Stem Cell from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did International Stem Cell pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of International Stem Cell in the year 2023?

In the year 2023, International Stem Cell distributed 0 USD as dividends.

In which currency does International Stem Cell pay out the dividend?

The dividends of International Stem Cell are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von International Stem Cell

Our stock analysis for International Stem Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of International Stem Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.